Press Releases

Date	Summary	View
Toggle SummarySep 26, 2019	RedHill Biopharma Provides H2/2019 R&D Update TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryAug 27, 2019	RedHill Biopharma to Present at Upcoming Investor Conferences in September TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryAug 21, 2019	RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryJul 23, 2019	RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia ® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019 Preparations ongoing for the potential U.S. ...	View HTML PDF Version
Toggle SummaryJul 15, 2019	RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019 TEL-AVIV, Israel and RALEIGH, N.C. , July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryJul 03, 2019	RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia® U.S. FDA accepts NDA for priority review PDUFA date set for November 2, 2019 H. pylori infection affects approximately 35% of the U.S. population and is the strongest risk factor for the development of gastric cancer and a major risk factor for peptic ulcer disease and MALT lymphoma TEL-AVIV, ...	View HTML PDF Version
Toggle SummaryJun 10, 2019	RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections The new patent expands the robust patent portfolio covering RHB-104 and RHB-204 RedHill plans to initiate a pivotal Phase 3 study with RHB-204 for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections in the second half of 2019 RedHill plans to meet with the FDA in the second ...	View HTML PDF Version
Toggle SummaryMay 28, 2019	RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer TEL-AVIV, Israel and RALEIGH, N.C. , May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. ...	View HTML PDF Version
Toggle SummaryMay 23, 2019	RedHill Biopharma to Present at 2019 BIO International Convention TEL-AVIV, Israel and RALEIGH, N.C. , May 23, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...	View HTML PDF Version
Toggle SummaryMay 21, 2019	RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch Rob Jackson joins as Vice President of Marketing Robert J. Gilkin, Jr. joins as Vice President of Market Access Steven Thomasian to join as Vice President of Supply Chain TEL-AVIV, Israel and RALEIGH, N.C. , May 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...	View HTML PDF Version

Subscribe to press releases